featured
Dasatinib With Trastuzumab and Paclitaxel Feasible in First Line for HER2-Overexpressing Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Oncotarget
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase I Study of the SRC Kinase Inhibitor Dasatinib With Trastuzumab and Paclitaxel as First Line Therapy for Patients With HER2-Overexpressing Advanced Breast Cancer. GEICAM/2010-04 Study
Oncotarget 2017 Apr 14;[EPub Ahead of Print], A Ocana, M Gil-Martin, M Martín, F Rojo, S Antolín, Á Guerrero, JM Trigo, M Muñoz, A Pandiella, NG Diego, S Bezares, R Caballero, E Carrasco, A UrruticoecheaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.